Drug Safety

, Volume 26, Issue 9, pp 625–641 | Cite as

Benefit-Risk Assessment of Treatments for Heparin-Induced Thrombocytopenia

  • Harry L. Messmore
  • Walter P. Jeske
  • William H. Wehrmacher
  • Jeanine M. Walenga
Review Article

Abstract

Patients with heparin-induced thrombocytopenia (HIT) are at high risk of thrombosis and should be treated with alternative anticoagulant therapy to reduce complications. The current treatment of choice is one of the approved direct thrombin inhibitors, argatroban or lepirudin. These drugs have been proven to be safe and effective in multicentre clinical trials where dosage regimens have been established for prophylaxis and treatment of thrombosis. Argatroban has also been tested and approved for use in invasive cardiology procedures in the HIT patient. Dosage regimens for other clinical uses, such as cardiac surgery, have not yet been established for either drug. The safety and effectiveness of the thrombin inhibitors is dependent on their use according to established guidelines. Other treatment options that may be effective for the patient with HIT include dextran, plasmapheresis, intravenous gammaglobulin and aspirin (acetylsalicylic acid). Although used historically, these options have not been tested in rigorous clinical trials. For life- and limb-threatening thrombosis, thrombolytic agents and/or surgery may provide benefit. Because the risk of bleeding is high from these procedures, they should be performed only by an experienced practitioner. Several studies have shown that patients with HIT requiring continued anticoagulation are best managed with a warfarin derivative initiated while under full anticoagulation with a thrombin inhibitor. There is a risk of skin necrosis and bleeding if guidelines for dose administration and monitoring of warfarin are not followed. Subsequent use of heparin or a low molecular weight heparin after resolution of the clinical episode of HIT can be hazardous, particularly within the first 3 months. If laboratory testing is negative, heparin may be cautiously reinstituted for short-term use (1–2 hours) with monitoring for platelet count decrease and thromboembolism. The pregnant patient with HIT requiring anticoagulation represents a particular challenge, where there is no drug of choice at present. Although today there are realistic treatment options for the patient with HIT, the morbidity and mortality associated with this disease have not been eliminated. Awareness and early treatment of HIT remain important components of the clinical care for patients exposed to heparins. Future therapeutic developments based on a better understanding of the pathophysiology of HIT may further improve clinical outcomes. Despite some limitations, the current treatment options for patients with HIT provide unparalleled benefit compared with the treatment options available only a few years ago.

Notes

Acknowledgements

Jeanine Walenga is a consultant to GlaxoSmithKline and to Berlex. No sources of funding were used to assist in the preparation of this manuscript.

References

  1. 1.
    Lee DH, Warkentin TE. Frequency of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia. 2nd rev. ed. New York: Marcel Dekker, 2001: 87–121Google Scholar
  2. 2.
    Powers PJ, Cuthbert D, Hirsh J. Thrombocytopenia found uncommonly during heparin therapy. JAMA 1979; 241: 2396–7PubMedCrossRefGoogle Scholar
  3. 3.
    Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low molecular weight heparin or unfractionated heparin. N Engl J Med 1995; 332: 1330–5PubMedCrossRefGoogle Scholar
  4. 4.
    Weismann RE, Tobin RW. Arterial embolism occurring systemic heparin therapy. Arch Surg 1958; 76: 219–27CrossRefGoogle Scholar
  5. 5.
    Roberts B, Rosato FE, Rosato EF. Heparin - a cause of arterial emboli? Surgery 1964; 55: 803–8PubMedGoogle Scholar
  6. 6.
    Natelson EA, Lynch EC, Alfrey CP, et al. Heparin-induced thrombocytopenia. Ann Intern Med 1969; 71: 1121–5PubMedGoogle Scholar
  7. 7.
    Bell WR, Tomasulo PA, Alving BM, et al. Thrombocytopenia occurring during the administration of heparin. A prospective study in 52 patients. Ann Intern Med 1976; 85: 155–60PubMedGoogle Scholar
  8. 8.
    Israels ED, Nisli D, Paraskevas F, et al. Platelet Fc receptor as a mechanism for Ag-Ab complex induced platelet injury. Thromb Diath Haemorrh 1973; 29: 434–8PubMedGoogle Scholar
  9. 9.
    Chong BH, Grace CS, Rozenberg MC. Heparin-induced thrombocytopenia: effect of heparin platelet antibody on platelets. Br J Haematol 1981; 49: 531–6PubMedCrossRefGoogle Scholar
  10. 10.
    Messmore HL, Fareed J, Parvez Z, et al. Studies on the mechanism of heparin-induced thrombocytopenia. Thromb Haemost 1981; 46: 215Google Scholar
  11. 11.
    Kelton JG, Sheridan D, Brain H, et al. Clinical usefulness of testing for a heparin-dependent platelet aggregating factor in patients with suspected heparin associated thrombocytopenia. J Lab Clin Med 1984; 103: 606–12PubMedGoogle Scholar
  12. 12.
    Amiral J, Bridey F, Dreyfus M, et al. Platelet factor 4 complexed to heparin is the target for antibodies generated in heparin-induced thrombocytopenia [letter]. Thromb Haemost 1992; 68: 95PubMedGoogle Scholar
  13. 13.
    Visentin GP, Ford SE, Scott JP, et al. Antibodies from patients with heparin-induced thrombocytopenia are specific for platelet factor 4 complexed with heparin or bound to endothelial cells. J Clin Invest 1994; 93: 81–8PubMedCrossRefGoogle Scholar
  14. 14.
    Amiral J, Wolf F, Fisher AM, et al. Pathogenicity of IgA and/or IgM antibodies to heparin PF4 complexes in patients with heparin-induced thrombocytopenia. Br J Haematol 1996; 92: 954–9PubMedCrossRefGoogle Scholar
  15. 15.
    Denomme GA, Warkentin TE, Horsewood P, et al. Activation of platelets by sera containing IgG, heparin dependent antibodies: an explanation for the predominance of the FcγRIIa “low responder” (his 131) gene in patients with heparin-induced thrombocytopenia. J Lab Clin Med 1997; 130: 278–84PubMedCrossRefGoogle Scholar
  16. 16.
    Amiral J, Marfaing-Koka A, Wolf M, et al. Presence of auto-antibodies to interleukin-8 or neutrophile-activating peptide-2 in patients with heparin-associated thrombocytopenia. Blood 1996; 88: 410–6PubMedGoogle Scholar
  17. 17.
    Pouplard C, Lochmann S, Renard B, et al. Induction of monocyte tissue factor expression by antibodies to heparin-platelet factor 4 complexes developed in heparin-induced thrombocytopenia. Blood 2001; 97(10): 3300–2PubMedCrossRefGoogle Scholar
  18. 18.
    Jeske WP, Schlenker R, Bakhos M, et al. Are leukocytes important for platelet activation in heparin-induced thrombocytopenia? Ann Hematol 2000; 79Suppl. 1: A46Google Scholar
  19. 19.
    Fareed J, Walenga JM, Hoppensteadt DA, et al. Selectins in the HIT syndrome. Pathophysiologic role and therapeutic modulation. Semin Thromb Hemost 1999; 25Suppl. 1: 37–42PubMedGoogle Scholar
  20. 20.
    Warkentin TE. Clinical picture of heparin-induced thrombocytopenia. In: Warkentin TE, Greinacher A, editors. heparin-induced thrombocytopenia, 2nd rev. ed. New York: Marcel Dekker, 2001: 43–86Google Scholar
  21. 21.
    Wehrmacher W, Messmore H. Thrombocytopenia and thrombosis due to heparin. Cardiovasc Rev Rep 1998 Apr: 38–48Google Scholar
  22. 22.
    Messmore H, Upadhyay G, Farid S, et al. Heparin-induced thrombocytopenia and thrombosis in cardiovascular surgery. In: Pifarré R, editor. New anticoagulants for the cardiovascular patient. Philadelphia (PA): Hanley & Belfus, 1997: 83–94Google Scholar
  23. 23.
    Wallis D, Lewis B, Messmore H, et al. Heparin-induced thrombocytopenia and thrombosis syndrome. Clin Appl Thromb Hemost 1998; 4: 160–3CrossRefGoogle Scholar
  24. 24.
    Boshkov LK, Warkentin TE, Hayward CPM, et al. Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies. Br J Haematol 1993; 84: 322–8PubMedCrossRefGoogle Scholar
  25. 25.
    Beland B, Busse H, Loick HM, et al. Phlegmasia cerulea dolens, cerebral venous thrombosis, and fatal pulmonary embolism due to heparin-induced thrombocytopenia syndrome. Anesth Analg 1997; 85: 1272–4PubMedGoogle Scholar
  26. 26.
    Kappa JR, Fisher CA, Berkowitz HD, et al. Heparin-induced platelet activation in sixteen surgical patients: diagnosis and management. J Vasc Surg 1987; 5: 101–9PubMedGoogle Scholar
  27. 27.
    Warkentin TE, Kelton JG. Temporal aspects of heparin-induced thrombocytopenia. N Engl J Med 2001; 344: 1286–92PubMedCrossRefGoogle Scholar
  28. 28.
    Hirsh J, Warkentin T, Shaughnessy S, et al. Heparin and low-molecular weight heparin. Mechanisms of action, pharmacokinetics, dosing monitoring, efficacy and safety. Consensus Conference on Antithrombotic Therapy. Chest 2001 Jan; 119Suppl.: 64S–94SPubMedCrossRefGoogle Scholar
  29. 29.
    Wallis DE, Lewis BE, Messmore HL, et al. Inadequacy of current prevention strategies for heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 1999; 5Suppl. 1: 516–20Google Scholar
  30. 30.
    Walenga JM, Jeske W, Fasanella A, et al. Laboratory tests for the diagnosis of heparin-induced thrombocytopenia. Semin Thromb Hemost 1999; 25Suppl. 1: 43–9PubMedGoogle Scholar
  31. 31.
    Chong BH, Burgess J, Ismail F. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia. Thromb Haemost 1993; 69: 344–50PubMedGoogle Scholar
  32. 32.
    Schnell MK, Giordano KJ, Munezzo HM, et al. Diagnosis of heparin-induced thrombocytopenia (HIT): comparison of methods. Transfusion 1998; 38Suppl.: 98SGoogle Scholar
  33. 33.
    Izban KF, Lietz HW, Hoppensteadt DA, et al. Comparison of two PF4/heparin ELISA assays for the laboratory diagnosis of heparin-induced thrombocytopenia. Semin Thromb Hemost 1999; 25Suppl. 1: 51–6PubMedGoogle Scholar
  34. 34.
    Walenga JM, Jeske WP, Wood JJ, et al. Laboratory tests for heparin-induced thrombocytopenia. Semin Hematol 1999; 36(1 Suppl. 1): 22–8PubMedGoogle Scholar
  35. 35.
    Prechel M, Bano A, Drenth AF, et al. Assay selection and interpretation for laboratory testing of heparin-induced thrombocytopenia: diagnostic implications [abstract]. Blood 2001; 98(11): 36aGoogle Scholar
  36. 36.
    Greinacher A, Warkentin TE. Treatment of heparin-induced thrombocytopenia: an overview. In: Warkentin TE, Greinacher A, editors. Heparin-induced thrombocytopenia, 2nd rev. ed. New York: Marcel Dekker, 2001: 291–319Google Scholar
  37. 37.
    Pouplard C, Amiral J, Borg JY, et al. Decision analysis for use of platelet aggregation test, carbon 14-serotonin release assay, and heparin-platelet factor 4 enzyme-linked immunosorbent assay for diagnosis of heparin-induced thrombocytopenia. Am J Clin Pathol 1999; 111(5): 700–6PubMedGoogle Scholar
  38. 38.
    Greincher A, Eichler P, Lubenow N, et al. Heparin-induced thrombocytopenia with thromboembolic complications: meta-analysis of 2 prospective trials to assess the value of parental treatment with lepirudin and its therapeutic aPTT range. Blood 2000; 96: 846–51Google Scholar
  39. 39.
    Chong BH, Gallus AS, Cade JF, et al. Prospective randomized open-label comparison of danaparoid with dextran 70 in the treatment of heparin-induced thrombocytopenia with thrombosis. Thromb Haemost 2001; 86: 1170–5PubMedGoogle Scholar
  40. 40.
    Farag SS, Savora H, O’Malley CJ, et al. Lack of in-vitro cross reactivity predicts safety of low-molecular weight heparins in heparin-induced thrombocytopenia. Clin Appl Thromb Hemost 1997; 2: 58–62Google Scholar
  41. 41.
    Riess KFC, Lower C, Seelig C, et al. Recombinant hirudin as a new anticoagulant during cardiac operations instead of heparin: successful for aortic valve replacement in man. J Thorac Cardiovascular Surg 1995; 110: 265–7CrossRefGoogle Scholar
  42. 42.
    Matsuo T, Kario K, Chikahera Y, et al. Treatment of heparin-induced thrombocytopenia by use of argatroban, a synthetic thrombin inhibitor. Br J Haematol 1992; 82: 627–8PubMedCrossRefGoogle Scholar
  43. 43.
    Mehta DP, Yoder EL, Appel J, et al. Heparin-induced thrombocytopenia and thrombosis: reversal with streptokinase: a case report and review of the literature. Am J Hematol 1991; 36: 275–9PubMedCrossRefGoogle Scholar
  44. 44.
    Magnani HN. Heparin-induced thrombocytopenia (HIT): an overview of 230 patients treated with Orgaran (Org 10172). Thromb Haemost 1993; 70: 554–61PubMedGoogle Scholar
  45. 45.
    Ortel TL, Chong BH. New treatment options for heparin-induced thrombocytopenia. Semin Hematol 1998; 35: 26–34PubMedGoogle Scholar
  46. 46.
    Magnan H. Organon (danaparoid sodium) use in the syndrome of heparin-induced thrombocytopenia. Platelets 1997; 8: 74–81Google Scholar
  47. 47.
    Wilde MI, Markham A. Danaparoid: a review of it pharmacology and clinical use in the management of heparin-induced thrombocytopenia. Drugs 1997; 54(6): 903–24PubMedCrossRefGoogle Scholar
  48. 48.
    Walenga JM, Koza MJ, Lewis BE, et al. Relative heparin-induced thrombocytopenic potential of low molecular weight heparins and new antithrombotic agents. Clin Appl Thromb Hemost 1996; 2Suppl. 1: S21–7Google Scholar
  49. 49.
    Chong BH, Ismail F, Cade J, et al. Heparin-induced thrombocytopenia: studies with a new low molecular weight heparinoid, Org 10172. Blood 1989; 73 (6): 1592–6Google Scholar
  50. 50.
    Bauersachs RM, Lindhoff-Last E, Ehrly AM, et al. Treatment of hirudin overdosage in a patient with chronic renal failure. Thromb Haemost 1999; 81: 323–4PubMedGoogle Scholar
  51. 51.
    Koster A, Merkle F, Hansen R, et al. Elimination of recombinant hirudin by modified ultrafiltration during simulated cardiopulmonary bypass: assessment of different filter systems. Anesth Analg 2000; 91: 265–9PubMedGoogle Scholar
  52. 52.
    Walenga JM, Ahmad S, Hoppensteadt D, et al. Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia. Thromb Res 2002; 105: 401–5PubMedCrossRefGoogle Scholar
  53. 53.
    Lewis BE, Walenga JM, Hursting MJ. Argatroban anticoagulation in patients with heparin-induced thrombocytopenia. Cardiovasc Rev Rep 2002; 23: 445–54, 457Google Scholar
  54. 54.
    McKeage K, Plosker GL. Argatroban. Drugs 2001; 61(4): 515–522PubMedCrossRefGoogle Scholar
  55. 55.
    Swan SK, Hursting MJ. The pharmacokinetics and pharmacodynamics of argatroban: effects of age, gender, and hepatic or renal dysfunction. Pharmacotherapy 2000; 20: 318–29PubMedCrossRefGoogle Scholar
  56. 56.
    Swan SK, St Peter JV, Lambrecht LJ, et al. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects. Pharmacotherapy 2000; 20: 756–70PubMedCrossRefGoogle Scholar
  57. 57.
    Lewis BE, Wallis DE, Berkowitz SD, et al. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia. Circulation 2001; 103: 1838–43PubMedCrossRefGoogle Scholar
  58. 58.
    Lewis BE, Wallis DE, Zehnder JL, et al. Argatroban reexposure in patients with heparin-induced thrombocytopenia [abstract]. Blood 2000; 96Pt 1: 52aGoogle Scholar
  59. 59.
    Markwardt F. Hirudin: the promising antithrombotic. Cardiovasc Drug Rev 1992; 10: 211–32CrossRefGoogle Scholar
  60. 60.
    Eichler P, Friesen HJ, Lubenow N, et al. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: incidence, effects on aPTT and clinical relevance. Blood 2000; 96: 2373–8PubMedGoogle Scholar
  61. 61.
    Song X, Huhle G, Wang L, et al. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin. Circulation 1999; 100(14): 1528–32PubMedCrossRefGoogle Scholar
  62. 62.
    Refludan (lepirudin) package insert. Berlex Laboratories, Wayne (NJ) USAGoogle Scholar
  63. 63.
    Greinacher A, Volpel H, Janssens U, et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: a prospective study. Circulation 1999; 99: 73–80PubMedCrossRefGoogle Scholar
  64. 64.
    Greinacher A, Janssens U, Berg G, et al. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia. Circulation 1999; 100: 587–93PubMedCrossRefGoogle Scholar
  65. 65.
    Farner B, Eichler P, Kroll H, et al. A comparison of danaparoid and lepirudin in heparin-induced thrombocytopenia. Thromb Haemost 2001; 85: 950–7PubMedGoogle Scholar
  66. 66.
    Pötzsch B, Madlener K, Seelig C, et al. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass - assessment of the whole blood ecarin clotting time. Thromb Haemost 1997; 77(5): 920–5PubMedGoogle Scholar
  67. 67.
    Nurmohamed MT, Berckmans RJ, Morrien-Salomons WM, et al. Monitoring anticoagulant therapy by activated partial thromboplastin time: hirudin assessment. Thromb Haemost 1994; 72: 685–92PubMedGoogle Scholar
  68. 68.
    Walenga JM, Fasanella AR, Iqbal O, et al. Coagulation laboratory testing in patients treated with argatroban. Semin Thromb Hemost 1999; 25Suppl. 1: 61–6PubMedGoogle Scholar
  69. 69.
    Sheth SB, DiCicco RA, Hursting MJ, et al. Interpreting the international normalized ratio (INR) in individuals receiving argatroban and warfarin. Thromb Haemost 2001; 85: 435–40PubMedGoogle Scholar
  70. 70.
    Walenga JM, Drenth AF, Mayuga M, et al. Effects of argatroban alone and combined with oral anticoagulation on coagulation parameters [abstract]. Blood 2002; 100(11): 131bGoogle Scholar
  71. 71.
    Gossage JR. Early intervention in massive pulmonary embolism. Postgrad Med 2002; 111(3): 27–50PubMedCrossRefGoogle Scholar
  72. 72.
    Hyers T, Agnelli G, Huss R, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001; 119: 176S–93SPubMedCrossRefGoogle Scholar
  73. 73.
    Ohrman E, Harrington R, Carmen C, et al. Intravenous thrombolysis in acute myocardial infarction. Chest 2001; 119: 253S–77SCrossRefGoogle Scholar
  74. 74.
    Qurnones-Baldrich WJ, Baker JD, Busuttil R, et al. Intraoperative infusion of lytic drug for thrombotic complications of revascularization. J Vasc Surg 1989; 10: 408–17Google Scholar
  75. 75.
    Marder VJ. Thrombolytic therapy 2001. Blood Rev 2001; 15: 143–57PubMedCrossRefGoogle Scholar
  76. 76.
    Belkin M, Belkin B, Buckman C, et al. Intra-arterial thrombolytic therapy: efficacy of streptokinase vs. urokinase. Arch Surg 1986; 121: 769–73PubMedCrossRefGoogle Scholar
  77. 77.
    Working Party on Thrombolysis in the Management of Limb Ischemia. Thrombolysis in the management of limb arterial occlusion: towards a consensus interim report. J Intern Med 1996; 240: 343–55Google Scholar
  78. 78.
    Working Party on Thrombolysis in the Management of Limb Ischemia. Thrombolysis in the management of lower limb peripheral arterial occlusion — a consensus document. Am J Cardiol 1998; 81: 207–18Google Scholar
  79. 79.
    Lewis BE, Ferguson JJ, Grassman ED, et al. Successful coronary interventions performed with argatroban anticoagulation in patients with heparin-induced thrombocytopenia and thrombosis syndrome. J Invas Cardiol 1996; 8: 410–7Google Scholar
  80. 80.
    Lewis BE, Matthai WH, Cohen M, et al. Argatroban anticoagulation during percutaneous coronary intervention in patients with heparin-induced thrombocytopenia. Cathet Cardiovasc Intervent 2002; 57: 177–84CrossRefGoogle Scholar
  81. 81.
    Pötzsch B, Klovekorn WP. Use of heparin during cardiopulmonary bypass in patients with a history of heparin-induced thrombocytopenia. N Engl J Med 2000; 343(7): 515–6PubMedCrossRefGoogle Scholar
  82. 82.
    Olinger GN, Hussey CV, Olive JA, et al. Cardiopulmonary bypass for patients with previously documented heparin induced platelet aggregation. J Thorac Cardiovasc Surg 1984; 87: 673–7PubMedGoogle Scholar
  83. 83.
    Koster A, Kukucka M, Bach F, et al. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb-IIIa antagonist tirofiban. Anesthesiology 2001; 94: 245–51PubMedCrossRefGoogle Scholar
  84. 84.
    Koster A, Hansen R, Kuppe H, et al. Recombinant hirudin as an alternative for anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II: a 1-year experience in 57 patients. J Cardiothorac Vasc Anesth 2000; 14(3): 243–8PubMedCrossRefGoogle Scholar
  85. 85.
    Bauer M, Koster A, Pasic M, et al. Recombinant hirudin for extended aortic surgery in patients with heparin-induced thrombocytopenia. J Thorac Cardiovasc Surg 1999; 118(1): 191–2PubMedCrossRefGoogle Scholar
  86. 86.
    Riess FC, Kormann J, Pötzsch B. Recombinant hirudin as anticoagulant during cardiopulmonary bypass. Anesthesiology 2000; 93(6): 1551–2PubMedCrossRefGoogle Scholar
  87. 87.
    Koster A, Pasic M, Bauer M, et al. Hirudin as anticoagulant for cardiopulmonary bypass: importance of preoperative renal function. Ann Thorac Surg 2000; 69(1): 37–41PubMedCrossRefGoogle Scholar
  88. 88.
    Iqbal O, Gerdisc M, DaValle M, et al. Dosage optimization of antithrombin drugs using ecarin clotting time in patients with heparin-induced thrombocytopenia undergoing off-pump coronary artery revascularization and percutaneous coronary interventions [abstract]. J Clin Pharmacol 2000; 40(9): 1064Google Scholar
  89. 89.
    Koster A, Kuppe H, Crystal GJ, et al. Cardiovascular surgery without cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II using anticoagulation with recombinant hirudin. Anesth Analg 2000; 90: 292–9PubMedGoogle Scholar
  90. 90.
    Despotis GJ, Hogue CW, Saleem R, et al. The relationship between hirudin and activated clotting time: implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery. Anesth Analg 2001; 93: 28–32PubMedCrossRefGoogle Scholar
  91. 91.
    Lewis BE, Grassman ED, Wrona L, et al. Novastan anticoagulation during renal stent implant in a patient with heparin-induced thrombocytopenia. Blood Coagul Fibrinolysis 1997: 8(1): 54–8PubMedCrossRefGoogle Scholar
  92. 92.
    Lewis BE, Rangel Y, Fareed J. The first report of successful carotid stent implant using argatroban anticoagulation in a patient with heparin-induced thrombocytopenia and thrombosis syndrome. Angiology 1998; 49: 61–7PubMedCrossRefGoogle Scholar
  93. 93.
    Matsuo T, Chikahira Y, Yamada T, et al. Effect of synthetic thrombin inhibitor (MD805) as an alternative drug on heparin induced thrombocytopenia during hemodialysis. Thromb Res 1988; 52: 165–71PubMedCrossRefGoogle Scholar
  94. 94.
    Koide M, Yamamoto S, Matsuo M, et al. Anticoagulation for heparin-induced thrombocytopenia with spontaneous platelet aggregation in a patient requiring haemodialysis. Nephrol Dial Transplant 1995; 10: 2137–40PubMedGoogle Scholar
  95. 95.
    Steuer S, Boogen C, Plum J, et al. Anticoagulation with rhirudin in a patient with acute renal failure and heparin-induced thrombocytopenia. Nephrol Dial Transplant 1999; 14: 45–7PubMedCrossRefGoogle Scholar
  96. 96.
    Schneider T, Heuer B, Deller A, et al. Continuous haemofiltration with r-hirudin (lepirudin) as anticoagulant in a patient with heparin-induced thrombocytopenia (HIT II). Wien Klin Wochenschr 2000; 112: 552–5PubMedGoogle Scholar
  97. 97.
    Van Wyk V, Badenhorst PN, Luus HG, et al. A comparison between the use of recombinant hirudin and heparin during hemodialysis. Kidney Int 1995; 48: 1338–43PubMedCrossRefGoogle Scholar
  98. 98.
    Brady J, Riccio JA, Yumen OH, et al. Plasmapheresis: a therapeutic option in the management of heparin-associated thrombocytopenia with thrombosis. Am J Clin Pathol 1991; 96: 394–7PubMedGoogle Scholar
  99. 99.
    Greinacher A, Liebenhoff U, Kiefel V, et al. Heparin-associated thrombocytopenia: the effect of various intravenous IgG preparations on antibody mediated platelet activation - a possible new indication for high dose IVIg. Thromb Haemost 1994; 71 (5): 641–5Google Scholar
  100. 100.
    Reid T, Alving BM. Hirulog therapy for heparin-associated thrombocytopenia and deep venous thrombosis. Am J Hematol 1994; 45: 352–3PubMedCrossRefGoogle Scholar
  101. 101.
    Bivalirudin Investigators Brochure. Edition number 2001. 26 Oct 2001Google Scholar
  102. 102.
    Walenga JM, Jeske WP, Samama MM, et al. Fondaparinux: a synthetic heparin pentasaccharide as a new antithrombotic agent. Expert Opin Investig Drugs 2002; 11(3): 397–407PubMedCrossRefGoogle Scholar
  103. 103.
    Jeske WP, Jay AM, Haas S, et al. Heparin-induced thrombocytopenic potential of GAG and non-GAG based antithrombotic agents. Clin Appl Thromb Hemost 1999; 5Suppl. 1: S56–62PubMedCrossRefGoogle Scholar
  104. 104.
    Jeske WP, Walenga JM, Szatkowski E, et al. Effect of glycoprotein IIb/IIIa antagonists on the HIT serum induced activation of platelets. Thromb Res 1997; 88(3): 271–81PubMedCrossRefGoogle Scholar
  105. 105.
    Haas S, Walenga JM, Jeske WP, et al. Heparin-induced thrombocytopenia: the role of platelet activation and therapeutic implications. Semin Thromb Hemost 1999; 25Suppl. 1: 67–75PubMedGoogle Scholar
  106. 106.
    Walenga JM, Lewis BE, Jeske WP, et al. Combined thrombin and platelet inhibition treatment for HIT patients. Hämostaseologie 1999; 19: 128–33Google Scholar
  107. 107.
    Sharouni E, Oakley CM. Outcome pregnancy in women with valve prostheses. Br Heart J 1994; 7: 196–201CrossRefGoogle Scholar
  108. 108.
    Chan WS, Anand S, Ginsberg JS. Anticoagulation of pregnant women with mechanical heart valves: a systematic review of the literature. Arch Intern Med 2000; 160: 191–6PubMedCrossRefGoogle Scholar
  109. 109.
    Arnaout MS, Kazma H, Khalil A, et al. Is there a safe anticoagulation protocol for pregnant women with prosthetic heart valves? Clin Exp Obstet Gynecol 1998; 25: 101–4PubMedGoogle Scholar
  110. 110.
    Ginsberg JS, Greer I, Hirsh J. Use of antithrombotic agents during pregnancy. Chest 2001; 119Suppl.: 122–31CrossRefGoogle Scholar
  111. 111.
    Aijaz A, Nelson J, Naseer N. Management of heparin allergy in pregnancy. Am J Hematol 2001; 67 (4): 268–9CrossRefGoogle Scholar
  112. 112.
    Huhle G, Geberth M, Hoffmann U, et al. Management of heparin-associated thrombocytopenia in pregnancy with subcutaneous r-hirudin. Gynecol Obstet Invest 2000; 49(1): 67–9PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2003

Authors and Affiliations

  • Harry L. Messmore
    • 1
  • Walter P. Jeske
    • 2
  • William H. Wehrmacher
    • 3
  • Jeanine M. Walenga
    • 2
  1. 1.Department of MedicineHines Veterans Affairs Hospital, Hines, Illinois, and Loyola, University Medical CenterMaywoodUSA
  2. 2.Departments of Thoracic-Cardiovascular Surgery and PathologyCardiovascular Institute, Loyola University Medical CenterMaywoodUSA
  3. 3.Departments of Physiology and MedicineLoyola University Medical CenterMaywoodUSA

Personalised recommendations